The objective of the study was to investigate the efficacy of different dose levels of bopindolol monotherapy in hypertension. This potent nonselective beta-adrenergic receptor blocker has intrinsic sympathomimetic activity and long duration of action. Forty-four patients with essential hypertension of mild (n=40) or moderate (n=4) severity (90<DBP≤115 mmHg at the end of the placebo period) entered and completed the single-blind, placebo-controlled trial. The study lasted 14 weeks: 2 weeks on placebo, and 12 weeks on active treatment during which the initial dose of bipindolol, 1 mg daily, was augmented up to 1.5 mg, then to 2 mg at four-week intervals until BP normalized or a maximum dose of 2 mg/day bopindolol was reached. The bopindolol was administered once a day in the morning. Patients were seen every other week in the morning before drug taking, when BP and heart rate, supine and standing, a twelve lead ECG and side-effects were recorded. Compared with placebo, supine BP was significantly reduced by bopindolol: from 169±2/103±1 mmHg to 148±3/92±1, 144±3/90±1 and 136±2/85±0.6 mmHg at the end of 4, 8 and 12 weeks of treatments, respectively (P<0.01 for each). BP changes during standing were similar. Bopindolol lowered the supine heart rate from 84±2 to 75±1, 74±1, 72±1 beats/min (P<0.01). BP was normalized in all but two patients with a mean dose of 1.5 mg bopindolol daily. No side-effects of clinical importance were noted.
|Number of pages||3|
|Journal||Journal of Human Hypertension|
|Publication status||Published - Jan 1 1990|
ASJC Scopus subject areas
- Internal Medicine